Exact Mass: 514.2414

Telmisartan

C33H30N4O2 (514.2369)

Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2805 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.

Protoasukamycin

C31H34N2O5 (514.2468)

A polyketide that is (all-E)-7-(3-amino-4-hydroxyphenyl)hepta-2,4,6-trienoic acid in which the amino group has been acylated by an (all-E)-7-cyclohexylhepta-2,4,6-trienoyl group and in which the carboxy group has undergone formal condensation with the amino group of 2-amino-3-hydroxycyclopent-2-en-1-one to give the corresponding carboxamide. Protoasukamycin is an intermediate in the biosynthesis of asukamycin.

Lucidenic acid D2

C29H38O8 (514.2567)

Lucidenic acid D2 is found in mushrooms. Lucidenic acid D2 is a constituent of Ganoderma lucidum (reishi).

Glycinoeclepin C

C29H38O8 (514.2567)

Constituent of root of Phaseolus vulgaris (kidney bean). Glycinoeclepin C is found in pulses, yellow wax bean, and green bean. Glycinoeclepin C is found in pulses. Glycinoeclepin C is a constituent of root of Phaseolus vulgaris (kidney bean).

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C25H39O9P (514.2332)

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0)

C25H39O9P (514.2332)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C25H39O9P (514.2332)

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0)

C25H39O9P (514.2332)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0)

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0)

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0)

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C25H39O9P (514.2332)

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0)

C25H39O9P (514.2332)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Roridine E

C29H38O8 (514.2567)

9-Deacetyl-9-benzoyl-10-debenzoylbrevifoliol

C29H38O8 (514.2567)

Lucidenic acid D

C29H38O8 (514.2567)

Constituent of Ganoderma lucidum (reishi). Lucidenic acid D2 is found in mushrooms.

iso-Roridine E

C29H38O8 (514.2567)

CONFIDENCE isolated standard

roridin P

C29H38O8 (514.2567)

propindilactone N

C29H38O8 (514.2567)

C29H38O8

C29H38O8 (514.2567)

C21H38O14

C21H38O14 (514.2261)

Elaeodendroside D

C29H38O8 (514.2567)

Elaeodendroside L

C29H38O8 (514.2567)

novofumigatamide

C30H34N4O4 (514.258)

Nemorososide

C25H38O11 (514.2414)

2-O-Methylconfluentinsaeure|2-O-Methylconfluentsaeure

C29H38O8 (514.2567)

citreohybridone B|Citreohydridone B

C29H38O8 (514.2567)

4-butyl 1-(4-beta-D-glucopyranosyloxy-benzyl)ester (2R)-2-hydroxy-2-(2-methylpropyl)-butanedioic acid|armatuside|bletillin A

C25H38O11 (514.2414)

1alpha-methoxy-1,2-dihydrogedunin

C29H38O8 (514.2567)

15-isobutyrylhenrycinol A|henrycinol B

C31H34N2O5 (514.2468)

6R,7-dihydro-10-O-foliamenthoylaucubin

C25H38O11 (514.2414)

isocitreohybridone B

C29H38O8 (514.2567)

2-Hydroxyfissinolide

C29H38O8 (514.2567)

SETOSUSIN

C29H38O8 (514.2567)

(5R,6R,7R)-5,6,7,8-tetrahydro-1,2,3,10,11,12-hexamethoxy-6,7-dimethyldibenzo[a,c][8]annulen-5-yl (2Z)-2-methylbut-2-enoate|kadsufolin A

C29H38O8 (514.2567)

lagamboside

C27H34N2O8 (514.2315)

3beta-ACETOXYDEOXYANGOLENSIC ACID, METHYL ESTER

C29H38O8 (514.2567)

anemarrhena B

C32H34O6 (514.2355)

methyl 3beta-acetoxy-l-oxomeliacate

C29H38O8 (514.2567)

rhodomicranol A

C29H38O8 (514.2567)

wittifuran N

C29H38O8 (514.2567)

akuammidine 17-O-beta-d-glucopyranoside|methyl (19E)-17-(b-d-glucopyranosyloxy)-10-hydroxysarpagan-16-carboxylate

C27H34N2O8 (514.2315)

ingenol 3-angelate 5,20-diacetate|ingenol-3-angelate-5,20-diacetate

C29H38O8 (514.2567)

cinnacasside E

C25H38O11 (514.2414)

boletocrocin F

C27H34N2O8 (514.2315)

strictosidinic ketone

C27H34N2O8 (514.2315)

desacetylcinobufagin 3-succinate methyl ester

C29H38O8 (514.2567)

Elaphopilosin C

C29H38O8 (514.2567)

Phe Trp Tyr

C29H30N4O5 (514.2216)

Tyr Trp Phe

C29H30N4O5 (514.2216)

Trp Phe Tyr

C29H30N4O5 (514.2216)

Asn Gly Pro Val Glu

C21H34N6O9 (514.2387)

Phe Tyr Trp

C29H30N4O5 (514.2216)

Tyr Phe Trp

C29H30N4O5 (514.2216)

LucidenicacidD

C29H38O8 (514.2567)

Lucidenic acid D2 is a triterpenoid. Lucidenic acid D is a natural product found in Ganoderma sinense and Ganoderma lucidum with data available.

Telmisartan

C33H30N4O2 (514.2369)

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2251 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 63 CONFIDENCE standard compound; INTERNAL_ID 8191 This spectrum was obtained at The Multidisciplinary Research Laboratory at Antenor Orrego Private University, Trujillo, La Libertad, Peru.The sample was obtained from a pharmacy.; The sample was dissolved in 1:1 acetonitrile:water and passed through a ACQUITY UPLC BEH C18 1.7um column at 0.6 mL/min in ramp of MPA: 0.1\\\% Formic Acid in water; MPB: 0.1\\\% Formic Acid in Acetonitrile; Contact us: http://www.upao.edu.pe/labinm/ Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.

DIHYDROFISSINOLIDE_major

C29H38O8 (514.2567)

DIHYDROFISSINOLIDE_31.9\\%

C29H38O8 (514.2567)

Ala Phe Phe Met

C26H34N4O5S (514.225)

Ala Phe Met Phe

C26H34N4O5S (514.225)

Ala Met Phe Phe

C26H34N4O5S (514.225)

Ala Val Tyr Tyr

C26H34N4O7 (514.2427)

Ala Tyr Val Tyr

C26H34N4O7 (514.2427)

Ala Tyr Tyr Val

C26H34N4O7 (514.2427)

Cys Phe Phe Val

C26H34N4O5S (514.225)

Cys Phe Val Phe

C26H34N4O5S (514.225)

Cys His Lys Gln

C20H34N8O6S (514.2322)

Cys His Gln Lys

C20H34N8O6S (514.2322)

Cys Lys His Gln

C20H34N8O6S (514.2322)

Cys Lys Gln His

C20H34N8O6S (514.2322)

Cys Gln His Lys

C20H34N8O6S (514.2322)

Cys Gln Lys His

C20H34N8O6S (514.2322)

Cys Val Phe Phe

C26H34N4O5S (514.225)

Asp His Ile Met

C21H34N6O7S (514.221)

Asp His Leu Met

C21H34N6O7S (514.221)

Asp His Met Ile

C21H34N6O7S (514.221)

Asp His Met Leu

C21H34N6O7S (514.221)

Asp Ile His Met

C21H34N6O7S (514.221)

Asp Ile Met His

C21H34N6O7S (514.221)

Asp Leu His Met

C21H34N6O7S (514.221)

Asp Leu Met His

C21H34N6O7S (514.221)

Asp Met His Ile

C21H34N6O7S (514.221)

Asp Met His Leu

C21H34N6O7S (514.221)

Asp Met Ile His

C21H34N6O7S (514.221)

Asp Met Leu His

C21H34N6O7S (514.221)

Asp Pro Gln Arg

C20H34N8O8 (514.2499)

Asp Pro Arg Gln

C20H34N8O8 (514.2499)

Asp Gln Pro Arg

C20H34N8O8 (514.2499)

Asp Gln Arg Pro

C20H34N8O8 (514.2499)

Asp Arg Pro Gln

C20H34N8O8 (514.2499)

Asp Arg Gln Pro

C20H34N8O8 (514.2499)

Glu His Met Val

C21H34N6O7S (514.221)

Glu His Val Met

C21H34N6O7S (514.221)

Glu Met His Val

C21H34N6O7S (514.221)

Glu Met Val His

C21H34N6O7S (514.221)

Glu Asn Pro Arg

C20H34N8O8 (514.2499)

Glu Asn Arg Pro

C20H34N8O8 (514.2499)

Glu Pro Asn Arg

C20H34N8O8 (514.2499)

Glu Pro Arg Asn

C20H34N8O8 (514.2499)

Glu Arg Asn Pro

C20H34N8O8 (514.2499)

Glu Arg Pro Asn

C20H34N8O8 (514.2499)

Glu Val His Met

C21H34N6O7S (514.221)

Glu Val Met His

C21H34N6O7S (514.221)

Phe Ala Phe Met

C26H34N4O5S (514.225)

Phe Ala Met Phe

C26H34N4O5S (514.225)

Phe Cys Phe Val

C26H34N4O5S (514.225)

Phe Cys Val Phe

C26H34N4O5S (514.225)

Phe Phe Ala Met

C26H34N4O5S (514.225)

Phe Phe Cys Val

C26H34N4O5S (514.225)

Phe Phe Met Ala

C26H34N4O5S (514.225)

Phe Phe Thr Thr

C26H34N4O7 (514.2427)

Phe Phe Val Cys

C26H34N4O5S (514.225)

Phe Met Ala Phe

C26H34N4O5S (514.225)

Phe Met Phe Ala

C26H34N4O5S (514.225)

Phe Ser Val Tyr

C26H34N4O7 (514.2427)

Phe Ser Tyr Val

C26H34N4O7 (514.2427)

Phe Thr Phe Thr

C26H34N4O7 (514.2427)

Phe Thr Thr Phe

C26H34N4O7 (514.2427)

Phe Val Cys Phe

C26H34N4O5S (514.225)

Phe Val Phe Cys

C26H34N4O5S (514.225)

Phe Val Ser Tyr

C26H34N4O7 (514.2427)

Phe Val Tyr Ser

C26H34N4O7 (514.2427)

Phe Tyr Ser Val

C26H34N4O7 (514.2427)

Phe Tyr Val Ser

C26H34N4O7 (514.2427)

Gly Ile Tyr Tyr

C26H34N4O7 (514.2427)

Gly Leu Tyr Tyr

C26H34N4O7 (514.2427)

Gly Tyr Ile Tyr

C26H34N4O7 (514.2427)

Gly Tyr Leu Tyr

C26H34N4O7 (514.2427)

Gly Tyr Tyr Ile

C26H34N4O7 (514.2427)

Gly Tyr Tyr Leu

C26H34N4O7 (514.2427)

His Cys Lys Gln

C20H34N8O6S (514.2322)

His Cys Gln Lys

C20H34N8O6S (514.2322)

His Asp Ile Met

C21H34N6O7S (514.221)

His Asp Leu Met

C21H34N6O7S (514.221)

His Asp Met Ile

C21H34N6O7S (514.221)

His Asp Met Leu

C21H34N6O7S (514.221)

His Glu Met Val

C21H34N6O7S (514.221)

His Glu Val Met

C21H34N6O7S (514.221)

His Ile Asp Met

C21H34N6O7S (514.221)

His Ile Met Asp

C21H34N6O7S (514.221)

His Lys Cys Gln

C20H34N8O6S (514.2322)

His Lys Gln Cys

C20H34N8O6S (514.2322)

His Leu Asp Met

C21H34N6O7S (514.221)

His Leu Met Asp

C21H34N6O7S (514.221)

His Met Asp Ile

C21H34N6O7S (514.221)

His Met Asp Leu

C21H34N6O7S (514.221)

His Met Glu Val

C21H34N6O7S (514.221)

His Met Ile Asp

C21H34N6O7S (514.221)

His Met Leu Asp

C21H34N6O7S (514.221)

His Met Val Glu

C21H34N6O7S (514.221)

His Pro Val Tyr

C25H34N6O6 (514.254)

His Pro Tyr Val

C25H34N6O6 (514.254)

His Gln Cys Lys

C20H34N8O6S (514.2322)

His Gln Lys Cys

C20H34N8O6S (514.2322)

His Val Glu Met

C21H34N6O7S (514.221)

His Val Met Glu

C21H34N6O7S (514.221)

His Val Pro Tyr

C25H34N6O6 (514.254)

His Val Tyr Pro

C25H34N6O6 (514.254)

His Tyr Pro Val

C25H34N6O6 (514.254)

His Tyr Val Pro

C25H34N6O6 (514.254)

Ile Asp His Met

C21H34N6O7S (514.221)

Ile Asp Met His

C21H34N6O7S (514.221)

Ile Gly Tyr Tyr

C26H34N4O7 (514.2427)

Ile His Asp Met

C21H34N6O7S (514.221)

Ile His Met Asp

C21H34N6O7S (514.221)

Ile Met Asp His

C21H34N6O7S (514.221)

Ile Met His Asp

C21H34N6O7S (514.221)

Ile Tyr Gly Tyr

C26H34N4O7 (514.2427)

Ile Tyr Tyr Gly

C26H34N4O7 (514.2427)

Lys Cys His Gln

C20H34N8O6S (514.2322)

Lys Cys Gln His

C20H34N8O6S (514.2322)

Lys His Cys Gln

C20H34N8O6S (514.2322)

Lys His Gln Cys

C20H34N8O6S (514.2322)

Trp Tyr Phe

C29H30N4O5 (514.2216)

Lys Gln Cys His

C20H34N8O6S (514.2322)

Lys Gln His Cys

C20H34N8O6S (514.2322)

Leu Asp His Met

C21H34N6O7S (514.221)

Leu Asp Met His

C21H34N6O7S (514.221)

Leu Gly Tyr Tyr

C26H34N4O7 (514.2427)

Leu His Asp Met

C21H34N6O7S (514.221)

Leu His Met Asp

C21H34N6O7S (514.221)

Leu Met Asp His

C21H34N6O7S (514.221)

Leu Met His Asp

C21H34N6O7S (514.221)

Leu Tyr Gly Tyr

C26H34N4O7 (514.2427)

Leu Tyr Tyr Gly

C26H34N4O7 (514.2427)

Met Ala Phe Phe

C26H34N4O5S (514.225)

Met Asp His Ile

C21H34N6O7S (514.221)

Met Asp His Leu

C21H34N6O7S (514.221)

Met Asp Ile His

C21H34N6O7S (514.221)

Met Asp Leu His

C21H34N6O7S (514.221)

Met Glu His Val

C21H34N6O7S (514.221)

Met Glu Val His

C21H34N6O7S (514.221)

Met Phe Ala Phe

C26H34N4O5S (514.225)

Met Phe Phe Ala

C26H34N4O5S (514.225)

Met His Asp Ile

C21H34N6O7S (514.221)

Met His Asp Leu

C21H34N6O7S (514.221)

Met His Glu Val

C21H34N6O7S (514.221)

Met His Ile Asp

C21H34N6O7S (514.221)

Met His Leu Asp

C21H34N6O7S (514.221)

Met His Val Glu

C21H34N6O7S (514.221)

Met Ile Asp His

C21H34N6O7S (514.221)

Met Ile His Asp

C21H34N6O7S (514.221)

Met Leu Asp His

C21H34N6O7S (514.221)

Met Leu His Asp

C21H34N6O7S (514.221)

Met Val Glu His

C21H34N6O7S (514.221)

Met Val His Glu

C21H34N6O7S (514.221)

Asn Glu Pro Arg

C20H34N8O8 (514.2499)

Asn Glu Arg Pro

C20H34N8O8 (514.2499)

Asn Pro Glu Arg

C20H34N8O8 (514.2499)

Asn Pro Arg Glu

C20H34N8O8 (514.2499)

Asn Pro Val Trp

C25H34N6O6 (514.254)

Asn Pro Trp Val

C25H34N6O6 (514.254)

Asn Arg Glu Pro

C20H34N8O8 (514.2499)

Asn Arg Pro Glu

C20H34N8O8 (514.2499)

Asn Val Pro Trp

C25H34N6O6 (514.254)

Asn Val Trp Pro

C25H34N6O6 (514.254)

Asn Trp Pro Val

C25H34N6O6 (514.254)

Asn Trp Val Pro

C25H34N6O6 (514.254)

Pro Asp Gln Arg

C20H34N8O8 (514.2499)

Pro Asp Arg Gln

C20H34N8O8 (514.2499)

Pro Glu Asn Arg

C20H34N8O8 (514.2499)

Pro Glu Arg Asn

C20H34N8O8 (514.2499)

Pro His Val Tyr

C25H34N6O6 (514.254)

Pro His Tyr Val

C25H34N6O6 (514.254)

Pro Asn Glu Arg

C20H34N8O8 (514.2499)

Pro Asn Arg Glu

C20H34N8O8 (514.2499)

Pro Asn Val Trp

C25H34N6O6 (514.254)

Pro Asn Trp Val

C25H34N6O6 (514.254)

Pro Gln Asp Arg

C20H34N8O8 (514.2499)

Pro Gln Arg Asp

C20H34N8O8 (514.2499)

Pro Arg Asp Gln

C20H34N8O8 (514.2499)

Pro Arg Glu Asn

C20H34N8O8 (514.2499)

Pro Arg Asn Glu

C20H34N8O8 (514.2499)

Pro Arg Gln Asp

C20H34N8O8 (514.2499)

Pro Val His Tyr

C25H34N6O6 (514.254)

Pro Val Asn Trp

C25H34N6O6 (514.254)

Pro Val Trp Asn

C25H34N6O6 (514.254)

Pro Val Tyr His

C25H34N6O6 (514.254)

Pro Trp Asn Val

C25H34N6O6 (514.254)

Pro Trp Val Asn

C25H34N6O6 (514.254)

Pro Tyr His Val

C25H34N6O6 (514.254)

Pro Tyr Val His

C25H34N6O6 (514.254)

Gln Cys His Lys

C20H34N8O6S (514.2322)

Gln Cys Lys His

C20H34N8O6S (514.2322)

Gln Asp Pro Arg

C20H34N8O8 (514.2499)

Gln Asp Arg Pro

C20H34N8O8 (514.2499)

Gln His Cys Lys

C20H34N8O6S (514.2322)

Gln His Lys Cys

C20H34N8O6S (514.2322)

Gln Lys Cys His

C20H34N8O6S (514.2322)

Gln Lys His Cys

C20H34N8O6S (514.2322)

Gln Pro Asp Arg

C20H34N8O8 (514.2499)

Gln Pro Arg Asp

C20H34N8O8 (514.2499)

Gln Arg Asp Pro

C20H34N8O8 (514.2499)

Gln Arg Pro Asp

C20H34N8O8 (514.2499)

Arg Asp Pro Gln

C20H34N8O8 (514.2499)

Arg Asp Gln Pro

C20H34N8O8 (514.2499)

Arg Glu Asn Pro

C20H34N8O8 (514.2499)

Arg Glu Pro Asn

C20H34N8O8 (514.2499)

Arg Asn Glu Pro

C20H34N8O8 (514.2499)

Arg Asn Pro Glu

C20H34N8O8 (514.2499)

Arg Pro Asp Gln

C20H34N8O8 (514.2499)

Arg Pro Glu Asn

C20H34N8O8 (514.2499)

Arg Pro Asn Glu

C20H34N8O8 (514.2499)

Arg Pro Gln Asp

C20H34N8O8 (514.2499)

Arg Gln Asp Pro

C20H34N8O8 (514.2499)

Arg Gln Pro Asp

C20H34N8O8 (514.2499)

Ser Phe Val Tyr

C26H34N4O7 (514.2427)

Ser Phe Tyr Val

C26H34N4O7 (514.2427)

Ser Val Phe Tyr

C26H34N4O7 (514.2427)

Ser Val Tyr Phe

C26H34N4O7 (514.2427)

Ser Tyr Phe Val

C26H34N4O7 (514.2427)

Ser Tyr Val Phe

C26H34N4O7 (514.2427)

Thr Phe Phe Thr

C26H34N4O7 (514.2427)

Thr Phe Thr Phe

C26H34N4O7 (514.2427)

Thr Thr Phe Phe

C26H34N4O7 (514.2427)

Val Ala Tyr Tyr

C26H34N4O7 (514.2427)

Val Cys Phe Phe

C26H34N4O5S (514.225)

Val Glu His Met

C21H34N6O7S (514.221)

Val Glu Met His

C21H34N6O7S (514.221)

Val Phe Cys Phe

C26H34N4O5S (514.225)

Val Phe Phe Cys

C26H34N4O5S (514.225)

Val Phe Ser Tyr

C26H34N4O7 (514.2427)

Val Phe Tyr Ser

C26H34N4O7 (514.2427)

Val His Glu Met

C21H34N6O7S (514.221)

Val His Met Glu

C21H34N6O7S (514.221)

Val His Pro Tyr

C25H34N6O6 (514.254)

Val His Tyr Pro

C25H34N6O6 (514.254)

Val Met Glu His

C21H34N6O7S (514.221)

Val Met His Glu

C21H34N6O7S (514.221)

Val Asn Pro Trp

C25H34N6O6 (514.254)

Val Asn Trp Pro

C25H34N6O6 (514.254)

Val Pro His Tyr

C25H34N6O6 (514.254)

Val Pro Asn Trp

C25H34N6O6 (514.254)

Val Pro Trp Asn

C25H34N6O6 (514.254)

Val Pro Tyr His

C25H34N6O6 (514.254)

Val Ser Phe Tyr

C26H34N4O7 (514.2427)

Val Ser Tyr Phe

C26H34N4O7 (514.2427)

Val Trp Asn Pro

C25H34N6O6 (514.254)

Val Trp Pro Asn

C25H34N6O6 (514.254)

Val Tyr Ala Tyr

C26H34N4O7 (514.2427)

Val Tyr Phe Ser

C26H34N4O7 (514.2427)

Val Tyr His Pro

C25H34N6O6 (514.254)

Val Tyr Pro His

C25H34N6O6 (514.254)

Val Tyr Ser Phe

C26H34N4O7 (514.2427)

Val Tyr Tyr Ala

C26H34N4O7 (514.2427)

Trp Asn Pro Val

C25H34N6O6 (514.254)

Trp Asn Val Pro

C25H34N6O6 (514.254)

Trp Pro Asn Val

C25H34N6O6 (514.254)

Trp Pro Val Asn

C25H34N6O6 (514.254)

Trp Val Asn Pro

C25H34N6O6 (514.254)

Trp Val Pro Asn

C25H34N6O6 (514.254)

Tyr Ala Val Tyr

C26H34N4O7 (514.2427)

Tyr Ala Tyr Val

C26H34N4O7 (514.2427)

Tyr Phe Ser Val

C26H34N4O7 (514.2427)

Tyr Phe Val Ser

C26H34N4O7 (514.2427)

Tyr Gly Ile Tyr

C26H34N4O7 (514.2427)

Tyr Gly Leu Tyr

C26H34N4O7 (514.2427)

Tyr Gly Tyr Ile

C26H34N4O7 (514.2427)

Tyr Gly Tyr Leu

C26H34N4O7 (514.2427)

Tyr His Pro Val

C25H34N6O6 (514.254)

Tyr His Val Pro

C25H34N6O6 (514.254)

Tyr Ile Gly Tyr

C26H34N4O7 (514.2427)

Tyr Ile Tyr Gly

C26H34N4O7 (514.2427)

Tyr Leu Gly Tyr

C26H34N4O7 (514.2427)

Tyr Leu Tyr Gly

C26H34N4O7 (514.2427)

Tyr Pro His Val

C25H34N6O6 (514.254)

Tyr Pro Val His

C25H34N6O6 (514.254)

Tyr Ser Phe Val

C26H34N4O7 (514.2427)

Tyr Ser Val Phe

C26H34N4O7 (514.2427)

Tyr Val Ala Tyr

C26H34N4O7 (514.2427)

Tyr Val Phe Ser

C26H34N4O7 (514.2427)

Tyr Val His Pro

C25H34N6O6 (514.254)

Tyr Val Pro His

C25H34N6O6 (514.254)

Tyr Val Ser Phe

C26H34N4O7 (514.2427)

Tyr Val Tyr Ala

C26H34N4O7 (514.2427)

Tyr Tyr Ala Val

C26H34N4O7 (514.2427)

Tyr Tyr Gly Ile

C26H34N4O7 (514.2427)

Tyr Tyr Gly Leu

C26H34N4O7 (514.2427)

Tyr Tyr Ile Gly

C26H34N4O7 (514.2427)

Tyr Tyr Leu Gly

C26H34N4O7 (514.2427)

Tyr Tyr Val Ala

C26H34N4O7 (514.2427)

DPNGL

C21H34N6O9 (514.2387)

NGPVE

C21H34N6O9 (514.2387)

DIHYDROFISSINOLIDE

C29H38O8 (514.2567)

3β-ACETOXYDEOXYANGOLENSIC ACID, METHYL ESTER

C29H38O8 (514.2567)

Glycinoeclepin C

C29H38O8 (514.2567)

2-O-(beta-D-galactopyranosyl-(1->6)-beta-D-galactopyranosyl) 2S,3R-dihydroxynonanoic acid

C21H38O14 (514.2261)

AM-1638

C33H35FO4 (514.2519)

2-(chloromethyl)oxirane,4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methyloxirane,oxirane,propane-1,2,3-triol

C26H39ClO8 (514.2333)

4,4-(1,2-Ethenediyl)bis[N,N-diphenylbenzenamine]

C38H30N2 (514.2409)

hexanedioic acid,hexane-1,6-diol,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene

C27H34N2O8 (514.2315)

N,N-diphenyl-4-[2-[4-(N-phenylanilino)phenyl]ethenyl]aniline

C38H30N2 (514.2409)

Sobuzoxane

C22H34N4O10 (514.2275)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors

4-[(1,7-Dimethyl-2-propyl[2,5-bi-1H-benzimidazol]-1-yl)methyl][1,1-biphenyl]-2-carboxylic Acid

C33H30N4O2 (514.2369)

hexanedioic acid,hexane-1,6-diol,1-isocyanato-2-[(2-isocyanatophenyl)methyl]benzene

C27H34N2O8 (514.2315)

trans-Ned 19

C30H31FN4O3 (514.238)

17-(1-Hydroxyethyl)-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2-oxirane]-11,22-dione

C29H38O8 (514.2567)

PA(2:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C25H39O9P (514.2332)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0)

C25H39O9P (514.2332)

PA(2:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C25H39O9P (514.2332)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0)

C25H39O9P (514.2332)

PA(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C25H39O9P (514.2332)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0)

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0)

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0)

C25H39O9P (514.2332)

PA(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C25H39O9P (514.2332)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0)

C25H39O9P (514.2332)

1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid

C30H31FN4O3 (514.238)

1,2-Diheptanoyl-1,2-dithio-sn-glycero-3-phosphocholine

C22H45NO6PS2+ (514.2426)

Phe-Trp-Tyr

C29H30N4O5 (514.2216)

N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(4-methylpent-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyrazinecarboxamide

C26H34N4O5S (514.225)

N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-2-phenylethenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-3-ylacetamide

C30H34N4O4 (514.258)

1-(3-fluorophenyl)-3-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

(3aR,4R,9bS)-8-[3-[dimethylamino(oxo)methyl]phenyl]-4-(hydroxymethyl)-N-(4-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C30H34N4O4 (514.258)

(4R,7R,8S)-N-(2-fluorophenyl)-8-methoxy-4,7,10-trimethyl-11-oxo-14-(1-oxopropylamino)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

1-(3-fluorophenyl)-3-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea

C27H35FN4O5 (514.2591)

(3aS,4S,9bR)-8-[3-[dimethylamino(oxo)methyl]phenyl]-4-(hydroxymethyl)-N-(4-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide

C30H34N4O4 (514.258)

(4-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

C30H31FN4O3 (514.238)

(4-fluorophenyl)-[(1S)-1-(hydroxymethyl)-7-methoxy-1-(3-pyridinylmethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanone

C30H31FN4O3 (514.238)

Phe-Tyr-Trp

C29H30N4O5 (514.2216)

Trp-Tyr-Phe

C29H30N4O5 (514.2216)

Trp-Phe-Tyr

C29H30N4O5 (514.2216)

Tyr-Phe-Trp

C29H30N4O5 (514.2216)

Tyr-Trp-Phe

C29H30N4O5 (514.2216)

(1R,3R,8R,17S,20Z,24R,25S,26S)-17-[(1S)-1-hydroxyethyl]-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2-oxirane]-11,22-dione

C29H38O8 (514.2567)

SQMG 13:0

C22H42O11S (514.2448)

LPA 22:6;O2

C25H39O9P (514.2332)

PA 18:4/4:1;O

C25H39O9P (514.2332)

PA 22:5;O

C25H39O9P (514.2332)

PEth 20:5;O

C25H39O9P (514.2332)

PM 21:5;O

C25H39O9P (514.2332)

ST 19:1;O5;GlcA

C25H38O11 (514.2414)

ST 23:5;O2;GlcA

C29H38O8 (514.2567)

ST 19:2;O6;Hex

C25H38O11 (514.2414)

ST 23:6;O3;Hex

C29H38O8 (514.2567)

ST 25:3;O6;S

C25H38O9S (514.2236)

ST 26:2;O5;S

C26H42O8S (514.26)

ST 29:7;O3;S

C29H38O6S (514.2389)

ST 29:7;O8

C29H38O8 (514.2567)

Tripeptide-41

C29H30N4O5 (514.2216)

Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient[1].

1-[1-(4-ethyl-5-methyl-6-oxo-2,3-dihydropyran-2-yl)-1-hydroxyethyl]-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,9h,9bh,10h-cyclopenta[a]phenanthrene-5,8,11-trione

C29H38O8 (514.2567)

(3s,4as,6s,6ar,7r,10ar,10br)-6a-[(acetyloxy)methyl]-7-(chloromethyl)-7-hydroxy-4a,10b-dimethyl-5'-oxo-octahydrospiro[naphtho[2,1-b]pyran-3,3'-oxolan]-6-yl 2-methylpropanoate

C26H39ClO8 (514.2333)

(1'r,2s,3'r,8'r,12'e,17'r,18'e,20'z,24'r,25's)-17'-[(1s)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

6-(acetyloxy)-7-[(acetyloxy)methyl]-5-hydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-4-yl 2-methylbut-2-enoate

C29H38O8 (514.2567)

(2s)-2-{[(2e,4e,6e,8e,10e,12e,14e)-15-{[(1s,2s)-1-carboxy-2-methylbutyl]-c-hydroxycarbonimidoyl}-1-hydroxypentadeca-2,4,6,8,10,12,14-heptaen-1-ylidene]amino}pentanedioic acid

C27H34N2O8 (514.2315)

(1s,3ar,5ar,7r,9ar,9br,11ar)-1-[(1r)-1-[(2r)-4-ethyl-5-methyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,7h,9h,9bh,10h-cyclopenta[a]phenanthrene-5,8,11-trione

C29H38O8 (514.2567)

(1''r,2s,2'r,5''as,7''as,11''as,11''bs)-4,5,5'',5'',7''a,9'',11''b-heptamethyl-3,3'',5'-trioxo-2'',5''a,6'',7'',11'',11''a-hexahydro-1''h-dispiro[furan-2,4'-oxolane-2',8''-naphtho[2,1-c]oxepin]-1''-yl acetate

C29H38O8 (514.2567)

(11s,14r,16s,24s)-23-acetyl-10,13-dihydroxy-11-isopropyl-16-(2-methylbut-3-en-2-yl)-1,9,12,23-tetraazapentacyclo[12.10.0.0³,⁸.0¹⁶,²⁴.0¹⁷,²²]tetracosa-3,5,7,9,12,17,19,21-octaen-2-one

C30H34N4O4 (514.258)

(1s,2r,3r,4s,4ar,5r,8as)-3-(acetyloxy)-4-(benzoyloxy)-1-[(3e)-5-hydroxy-3-methylpent-3-en-1-yl]-5,8a-dimethyl-hexahydro-1h-spiro[naphthalene-2,2'-oxirane]-5-carboxylic acid

C29H38O8 (514.2567)

9-deacetyl-9-benzoyl-10-debenzoyl brevifoliol

C29H38O8 (514.2567)

{"Ingredient_id": "HBIN014079","Ingredient_name": "9-deacetyl-9-benzoyl-10-debenzoyl brevifoliol","Alias": "9-deacetyl-9-benzoyl-10-debenzoylbrevifoliol","Ingredient_formula": "C29H38O8","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C(=C)C3CC2(CC1O)C(C)(C)O)O)OC(=O)C)C)OC(=O)C4=CC=CC=C4)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26031;4728","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(11r,12r,15r,24s,25s)-12-hydroxy-18,19,20-trimethoxy-11,12,24,25-tetramethyl-4,6,9,14-tetraoxapentacyclo[13.7.3.0³,⁷.0⁸,²².0¹⁶,²¹]pentacosa-1(22),2,7,16(21),17,19-hexaen-13-one

C28H34O9 (514.2203)

(1'r,2s,3's,8's,12'e,17's,18'r,19'e,21'z,25'r,26's)-18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

[(1s,4as,5s,7ar)-5-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-7-yl]methyl (2e,6r)-8-hydroxy-2,6-dimethyloct-2-enoate

C25H38O11 (514.2414)

3-[(1r,5s,6r,10s,13s,14s)-5,10,14-trimethyl-6-[(2s)-2-methyloxiran-2-yl]-2,3,8-trioxo-14-(3-oxopentyl)-15-oxatetracyclo[8.6.0.0¹,¹³.0⁴,⁹]hexadec-4(9)-en-5-yl]propanoic acid

C29H38O8 (514.2567)

10-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(19),2(7),3,5,12,14(18)-hexaen-11-yl 2-methylbut-2-enoate

C28H34O9 (514.2203)

(1'r,3'r,8'r,12'z,19'z,21'z,25'r,26's)-18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl 2-methylbut-2-enoate

C29H38O8 (514.2567)

methyl 15-(acetyloxy)-8-methoxy-4,5,7,10,14,14-hexamethyl-6,18-dioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-3,7-diene-9-carboxylate

C29H38O8 (514.2567)

(8r,9s,10s)-9-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2z)-2-methylbut-2-enoate

C28H34O9 (514.2203)

(1s,3ar,5ar,8s,9ar,9br,11ar)-1-[(1r)-1-[(2r)-4-ethyl-5-methyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-3a,8-dihydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,8h,9h,9bh,10h-cyclopenta[a]phenanthrene-5,7,11-trione

C29H38O8 (514.2567)

3-[2-(furan-3-yl)-4-[4-methoxy-6-(2-methoxy-2-oxoethyl)-5,5,7-trimethyl-6,7-dihydro-4h-1-benzofuran-2-yl]-3-methyl-6-oxo-2h-pyran-3-yl]propanoic acid

C28H34O9 (514.2203)

12-hydroxy-18,19,20-trimethoxy-11,12,24,25-tetramethyl-4,6,9,14-tetraoxapentacyclo[13.7.3.0³,⁷.0⁸,²².0¹⁶,²¹]pentacosa-1(22),2,7,16(21),17,19-hexaen-13-one

C28H34O9 (514.2203)

(9s,10s,11s)-10-hydroxy-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(19),2(7),3,5,12,14(18)-hexaen-11-yl (2e)-2-methylbut-2-enoate

C28H34O9 (514.2203)

19-(furan-3-yl)-9,9,13,20-tetramethyl-5,17-dioxo-4,8,15,18-tetraoxahexacyclo[11.9.0.0²,⁷.0²,¹⁰.0¹⁴,¹⁶.0¹⁴,²⁰]docosan-12-yl acetate

C28H34O9 (514.2203)

1-(5-ethenyl-4-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-yl)ethanone

C27H34N2O8 (514.2315)

(1s,4ar,6r,6ar,8r,10r,10as,10bs)-6-(acetyloxy)-8-ethenyl-1,6a-dihydroxy-4,4,8,10b-tetramethyl-3,7-dioxo-hexahydro-1h-naphtho[1,2-c]pyran-10-yl benzoate

C28H34O9 (514.2203)

4-hydroxy-15-methoxy-2,14,17-trimethyl-3,11-dioxo-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadecan-16-yl 2h-1,3-benzodioxole-5-carboxylate

C28H34O9 (514.2203)

(5-hydroxy-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-7-yl)methyl 8-hydroxy-2,6-dimethyloct-2-enoate

C25H38O11 (514.2414)

1-[(4s,5r,6s)-5-ethenyl-4-[(1s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-yl]ethanone

C27H34N2O8 (514.2315)

4-butyl 1-(4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)methyl (2r)-2-hydroxy-2-(2-methylpropyl)butanedioate

C25H38O11 (514.2414)

(2s,3'r,8'r,12'e,17'r,18'e,20'z,24'r,25's)-17'-[(1r)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

4-[(3r,5s,9r,10s,12r,14r,15s,18r,22s,23r)-10,22-dihydroxy-9-methoxy-14,18-dimethyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosa-1,19-dien-19-yl]-5h-furan-2-one

C29H38O8 (514.2567)

4-butyl 1-(4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)methyl 2-hydroxy-2-(2-methylpropyl)butanedioate

C25H38O11 (514.2414)

(12'z,18'z,20'z)-17'-(1-hydroxyethyl)-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

23-acetyl-10,13-dihydroxy-11-isopropyl-16-(2-methylbut-3-en-2-yl)-1,9,12,23-tetraazapentacyclo[12.10.0.0³,⁸.0¹⁶,²⁴.0¹⁷,²²]tetracosa-3,5,7,9,12,17,19,21-octaen-2-one

C30H34N4O4 (514.258)

(1'r,2s,3'r,8'r,12'z,17's,18'z,20'z,24'r,25's)-17'-[(1s)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

1-[1-(4-ethyl-5-methyl-6-oxo-2,3-dihydropyran-2-yl)-1-hydroxyethyl]-3a,8-dihydroxy-9a,11a-dimethyl-1h,2h,3h,5ah,6h,8h,9h,9bh,10h-cyclopenta[a]phenanthrene-5,7,11-trione

C29H38O8 (514.2567)

(18'e)-17'-(1-hydroxyethyl)-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

2-butanoyl-6-[(3-butanoyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-3,5-dihydroxy-4-methyl-4-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-one

C29H38O8 (514.2567)

miophytocen a

C29H38O8 (514.2567)

methyl 15-(acetyloxy)-6-methoxy-4,5,7,10,14,14-hexamethyl-8,18-dioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-3,6-diene-9-carboxylate

C29H38O8 (514.2567)

methyl 2-[14-(acetyloxy)-6-(furan-3-yl)-8-hydroxy-1,5,15,15-tetramethyl-17-oxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-16-yl]acetate

C29H38O8 (514.2567)

(1'r,2s,12'z,17's,18's,19'z,21'z,25'r,26's)-18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

(2s,3'r,8'r,12'e,17's,18'e,20'e,24'r,25's)-17'-[(1s)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

(1'r,2s,3's,8'r,12'e,17'r,18'r,19'e,21'z,25'r,26's)-18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

(2s,3'r,8'r,12'z,18'z,20'z,24'r)-17'-(1-hydroxyethyl)-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

(1'r,2s,3'r,8'r,17'r,24'r,25's)-17'-[(1r)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

miophytocen b

C29H38O8 (514.2567)

4-[2,4-dimethoxy-6-(2-oxoheptyl)benzoyloxy]-2-methoxy-6-pentylbenzoic acid

C29H38O8 (514.2567)

4-{10,22-dihydroxy-9-methoxy-14,18-dimethyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosa-1,19-dien-19-yl}-5h-furan-2-one

C29H38O8 (514.2567)

methyl (1r,5r,9r,10s,12s,15s)-15-(acetyloxy)-6-methoxy-4,5,7,10,14,14-hexamethyl-8,18-dioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-3,6-diene-9-carboxylate

C29H38O8 (514.2567)

methyl (1r,5r,9r,10s,12s,15s)-15-(acetyloxy)-8-methoxy-4,5,7,10,14,14-hexamethyl-6,18-dioxo-19-oxapentacyclo[10.5.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadeca-3,7-diene-9-carboxylate

C29H38O8 (514.2567)

(1'r,2s,3'r,8'r,12'e,17's,18'e,20'e,24'r,25's)-17'-[(1s)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

roridin e

C29H38O8 (514.2567)

8-(acetyloxy)-2,6,10-trihydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-5-methylidene-2h,3h,4h,4ah,6h,7h,8h,9h,10h-cyclohexa[f]azulen-9-yl benzoate

C29H38O8 (514.2567)

methyl 2-[(1r,2s,5r,6r,8r,13s,14r,16s)-14-(acetyloxy)-6-(furan-3-yl)-8-hydroxy-1,5,15,15-tetramethyl-17-oxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-16-yl]acetate

C29H38O8 (514.2567)

(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl 1-methyl butanedioate

C29H38O8 (514.2567)

17'-(1-hydroxyethyl)-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

(19'e)-18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

(2s)-1-[(2s)-1-[(2s)-2-({[(2s,5s,6s)-6-(chloromethyl)-5-methoxypiperidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]piperidine-2-carbonyl]pyrrolidine-2-carboxylic acid

C24H39ClN4O6 (514.2558)

5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl 1-methyl butanedioate

C29H38O8 (514.2567)

4-[11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]pentanoic acid

C29H38O8 (514.2567)

(1s,2r,4s,7s,8s,11r,12r,13s,17r,19r)-7-(furan-3-yl)-13-methoxy-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadecan-19-yl acetate

C29H38O8 (514.2567)

(1's,2r,3'r,12'e,17'r,18'e,20'z,24'r,25's)-17'-[(1s)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

18'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24'-tetraoxaspiro[oxirane-2,27'-tetracyclo[23.2.1.0³,⁸.0⁸,²⁶]octacosane]-4',12',19',21'-tetraene-11',23'-dione

C29H38O8 (514.2567)

(1''s,2r,2's,5''ar,7''ar,11''ar,11''br)-4,5,5'',5'',7''a,9'',11''b-heptamethyl-3,3'',5'-trioxo-2'',5''a,6'',7'',11'',11''a-hexahydro-1''h-dispiro[furan-2,4'-oxolane-2',8''-naphtho[2,1-c]oxepin]-1''-yl acetate

C29H38O8 (514.2567)

7-(furan-3-yl)-13-methoxy-1,8,12,16,16-pentamethyl-5,15-dioxo-3,6-dioxapentacyclo[9.8.0.0²,⁴.0²,⁸.0¹²,¹⁷]nonadecan-19-yl acetate

C29H38O8 (514.2567)

(4r)-2-butanoyl-6-[(3-butanoyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-3,5-dihydroxy-4-methyl-4-(3-methylbut-2-en-1-yl)cyclohexa-2,5-dien-1-one

C29H38O8 (514.2567)

4-[(3r,5s,9s,10s,12r,14r,15s,18r,22s,23r)-10,22-dihydroxy-9-methoxy-14,18-dimethyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosa-1,19-dien-19-yl]-5h-furan-2-one

C29H38O8 (514.2567)

2-({15-[(1-carboxy-2-methylbutyl)-c-hydroxycarbonimidoyl]-1-hydroxypentadeca-2,4,6,8,10,12,14-heptaen-1-ylidene}amino)pentanedioic acid

C27H34N2O8 (514.2315)

(4s)-4-[(1r,3ar,5ar,9as,11s,11ar)-11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]pentanoic acid

C29H38O8 (514.2567)

(1s,4s,5r,6r,9s,10r,12r,14r)-6-(acetyloxy)-7-[(acetyloxy)methyl]-5-hydroxy-3,11,11,14-tetramethyl-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-4-yl (2z)-2-methylbut-2-enoate

C29H38O8 (514.2567)

(1'r,3'r,8'r,12'z,17'r,18'z,20'z,24'r,25's)-17'-[(1r)-1-hydroxyethyl]-5',13',25'-trimethyl-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',12',18',20'-tetraene-11',22'-dione

C29H38O8 (514.2567)

(8r,9r,10r)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl (2z)-2-methylbut-2-enoate

C29H38O8 (514.2567)

4,5,5'',5'',7''a,9'',11''b-heptamethyl-3,3'',5'-trioxo-2'',5''a,6'',7'',11'',11''a-hexahydro-1''h-dispiro[furan-2,4'-oxolane-2',8''-naphtho[2,1-c]oxepin]-1''-yl acetate

C29H38O8 (514.2567)